Compare Chevron Corp (CVX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Recursion Pharmaceuticals Inc — how do they compare? Chevron Corp trades at $210.32 (market cap $414.98B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: Chevron Corp is far larger — about 193.9× Recursion Pharmaceuticals Inc's market cap, and Chevron Corp pays a 3.37% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| CVX | RXRX | |
|---|---|---|
Market Cap | $414.98B | $2.14B |
Volume | 7,575,112 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $217.73 | $6.79 |
52-Week Low | $146.72 | $2.84 |
Typical Hold Time | 101 Days | 22 Days |
Enterprise Value | $443.52B | $1.66B |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $211.605, up 1.92% today, with a neutral technical signal. The stock shows strong earnings beats in recent quarters, with Q2 2026 EPS of $6.06 exceeding the $5.55 estimate. Revenue for 2025 was $184.43B, though net income declined to $12.30B. Analyst consensus is bullish with a $208.31 price target and 62% buy ratings. Recent news highlights Chevron's $13.8B investment in Argentina's Vaca Muerta and geopolitical impacts on oil prices.
The outlook for CVX is supported by high oil prices and strategic investments, but risks include volatile energy markets and declining profit margins. Earnings growth and dividend stability remain key catalysts, though geopolitical tensions and operational execution pose challenges for sustained shareholder returns.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
